DRY-CLOX DIN 02173247
Status: Marketed
Holder: BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
Molecule: CLOXACILLIN (CLOXACILLIN BENZATHINE)
Health Canada record
| Active ingredient(s) | CLOXACILLIN (CLOXACILLIN BENZATHINE) 500 MG |
|---|---|
| Dosage form | Gel |
| Route | Intramammary |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 18-Apr-2002 |
| Current status date | 10-Jun-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28776 | 2022-08-18 | Supplement to a New Drug Submission (SNDS) | MANUFACTURING PROCESS CHANGES TO STERILE API BATCH SIZZE AND PACKAGING |
| 26035 | 2021-06-10 | New Drug Submission (NDS) | CHANGE IN PRODUCT OWNERSHIP |
| 22205 | 2019-05-29 | Supplement to a New Drug Submission (SNDS) | MANUFACTURING CHANGE |
| 20083 | 2017-11-23 | Supplement to a New Drug Submission (SNDS) | MANUFACTURING CHANGES |
| 11604 | 2010-07-20 | New Drug Submission (NDS) | Change in ownership |
| 3490 | 2003-06-11 | New Drug Submission (NDS) | |
| 7108 | 1995-11-03 | New Drug Submission (NDS) |